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Abstract
Background: In Australia, the Home Medicines Review (HMR) is a nationally-funded program, led by
pharmacists to optimize medication use for older people. A Medicines Conversation Guide was
developed for pharmacists to use in the context of a HMR. The Guide aims to increase patient
involvement and support discussions about: general health understanding, decision-making and
information preferences, health priorities related to medicines, patient goals and fears, views on
important activities and trade-offs.
Objective: This study describes the development and feasibility testing of a Medicines Conversation
Guide in HMRs with pharmacists and older patients.
Methods: The Guide was developed using a systematic and iterative process, followed by testing in
clinical practice with 11 pharmacists, 17 patients (aged 65+) and their companions. A researcher
observed HMRs, surveyed and qualitatively interviewed patients and pharmacists to discuss feasibility.
Transcribed recordings of the interviews were thematically coded and a Framework Analysis method
used.
Results: Pharmacists found the Guide to be an acceptable and useful component to the HMR, especially
among patients with limited knowledge of their medicines. The Guide seemed most effective when
integrated with the HMR and tailored to suit the individual patient. Some questions were difficult for
patients to grasp (e.g. trade-offs) or sounded formal. Most patients found the Guide focused the HMR on
their perspective and encouraged a more holistic approach to the HMR. From the quantitative survey,
pharmacists found the Guide easy to implement, balanced and understandable.
Conclusions: Pharmacists and patients reported the Guide fits with the HMR encounter relatively easily
and promoted communication about goals and preferences in relation to medications. This study
highlighted some key challenges for communication about medicines and how the Guide may help
support the process of involving patients more in the HMR.

Disciplines
Education | Social and Behavioral Sciences

Publication Details
Weir, K. Rebecca., Bonner, C., McCaffery, K., Naganathan, V., Carter, S. M., Rigby, D., Trevena, L., McLachlan,
A. & Jansen, J. (2019). Pharmacists and patients sharing decisions about medicines: Development and
feasibility of a conversation guide. Research in Social and Administrative Pharmacy, 15 682-690.

Authors
Kristie Weir, Carissa Bonner, Kirsten McCaffery, Vasi Naganathan, Stacy M. Carter, Debbie Rigby, Lyndal
Trevena, Andrew J. McLachlan, and Jesse Jansen

This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/4407

Pharmacists and patients sharing decisions about medicines: Development and feasibility of a
conversation guide
Kristie Rebecca Weirab CarissaBonnerab Kirsten McCafferyab Vasi Naganathanch Stacy M.Carterd
Debbie Rigbye Lyndal Trevenaf Andrew McLachlancg Jesse Jansenab
a Wiser Healthcare, Sydney School of Public Health, The University of Sydney, NSW, 2006,
Australia
b Sydney Health Literacy Lab, Sydney School of Public Health, The University of Sydney, NSW,
2006, Australia
c Centre for Education and Research on Ageing (CERA), Concord Clinical School, The University of
Sydney, NSW, 2006, Australia
d Research for Social Change, Faculty of Social Science, The University of Wollongong, NSW, 2522,
Australia
e DR Pharmacy Consulting, Brisbane, QLD, Australia
f Ask Share Know Centre for Research Excellence, Sydney School of Public Health, The University
of Sydney, NSW, 2006, Australia
g Faculty of Pharmacy, University of Sydney, NSW, 2006, Australia
h Ageing and Alzheimer's Institute, Concord Repatriation General Hospital, NSW, 2139, Australia
Abstract
Background
In Australia, the Home Medicines Review (HMR) is a nationally-funded program, led by pharmacists
to optimize medication use for older people. A Medicines Conversation Guide was developed for
pharmacists to use in the context of a HMR. The Guide aims to increase patient involvement and
support discussions about: general health understanding, decision-making and information
preferences, health priorities related to medicines, patient goals and fears, views on important
activities and trade-offs.
Objective
This study describes the development and feasibility testing of a Medicines Conversation Guide in
HMRs with pharmacists and older patients.
Methods
The Guide was developed using a systematic and iterative process, followed by testing in clinical
practice with 11 pharmacists, 17 patients (aged 65+) and their companions. A researcher observed
HMRs, surveyed and qualitatively interviewed patients and pharmacists to discuss feasibility.
Transcribed recordings of the interviews were thematically coded and a Framework Analysis method
used.
Results
Pharmacists found the Guide to be an acceptable and useful component to the HMR, especially
among patients with limited knowledge of their medicines. The Guide seemed most effective when
integrated with the HMR and tailored to suit the individual patient. Some questions were difficult for
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patients to grasp (e.g. trade-offs) or sounded formal. Most patients found the Guide focused the HMR
on their perspective and encouraged a more holistic approach to the HMR. From the quantitative
survey, pharmacists found the Guide easy to implement, balanced and understandable.
Conclusions
Pharmacists and patients reported the Guide fits with the HMR encounter relatively easily and
promoted communication about goals and preferences in relation to medications. This study
highlighted some key challenges for communication about medicines and how the Guide may help
support the process of involving patients more in the HMR.
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Polypharmacy; Older people; Patient involvement; Goals; Preferences
1. Introduction
Medicines reviews are a structured approach to ensure the medicines an older person is taking are
appropriate. Similar pharmacy services and interventions exist internationally, for example, the
UK's medicines management services1 and the USA's medication therapy management,2 although
these services differ in several ways. In Australia, Home Medicines Reviews (HMRs) are
government-funded and conducted by an accredited pharmacist in the patient's home. HMRs must be
requested by a general practitioner (GP) and pharmacists receive a service fee of $219 upon
completion of the HMR.3 In order to fulfill HMR remuneration requirements, the pharmacist writes a
report to the referring GP based on which the GP formulates a medication plan. Comparatively,
medication review services in the UK and USA differ in the following ways: location of the review is
most often a pharmacy, review is requested by the dispensing pharmacist (UK), patient or other health
care provider (USA), and the patient's GP is only included when there is a problem or it is considered
necessary by the pharmacist (UK and USA).

Polypharmacy (taking 5 or more regular medications) is one of the main reasons an older person is
referred for a HMR.4 HMRs aim to resolve medication-related problems, encourage collaboration
between the patient, pharmacist and GP, and promote patient wellbeing.5,6 According to the HMR
Guidelines,7 the patient should be the main focus of the review reflecting the importance placed in the
literature on a patient-centred approach to medicines use.9,11 Depending on the individual older
patient's needs, this may lead to discussions about starting a medication, reducing the dose or stopping
medications. However, there is currently no formal structure embedding this into clinical practice and
the extent to which a patient is involved may vary considerably.

An important part of optimizing medications in an older person is to evaluate the evidence on
potential benefits and harms of medicines in light of his or her values, overall health and goals, and to
prioritize medicines accordingly.8, 9, 10, 11, 12 This is part of a shift towards goal-concordant care
for older patients and people with multi-morbidity, relying less on disease-specific
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guidelines/treatment in decisions about health.13 When evaluating medications, clinicians and patients
face complex trade-offs which can lead to an emphasis on preference-sensitive decisions.14,15There is
evidence that taking into account patient goals and preferences improves outcomes16 and this seems
particularly important for optimizing medicines for older patients.14 Even though patients vary in their
preference for involvement in health decisions, most older people want their perspectives to be
heard,17 so it is important for health care professionals to support communication and create
opportunities for this.

Tools to increase patient involvement in medical decisions have been developed, such as decision aids
and question prompt lists. Reviews have found that decision aids can increase value concordant
care18 and question prompt lists can support difficult discussions between clinician and patient (e.g.
regarding prognosis).19 As most of these tools are single-disease focused, none support the complex
decisions faced by an older person with comorbidities taking multiple medicines.14Furthermore, it is
unlikely a single decision aid could incorporate the relevant evidence for multiple chronic conditions,
medicines and combinations thereof,20 so a more flexible approach is needed. Emerging work in the
context of serious illness and chronic conditions demonstrates promising results for clinical encounter
discussion aids and conversation guides. They engage patients and clinicians in conversations about
preferences and prirorities to increase patient involvement, support health decisions and create a
quality interaction tailored to meet the needs of an individual.18,21
This research group developed the Medicines Conversation Guide, a tool designed to support
discussions about patient goals and preferences, and to improve the appropriate use of medicines. This
is particularly relevant in the context of inappropriate polypharmacy. A feasibility study was
performed to determine whether the Medicines Conversation Guide is suitable for further testing and
focused on the following: acceptability, practicality and implementation.

2. Methods
2.1. Overview of development and testing
Stage 1 of the development and testing of the Medicines Conversation Guide (Figure 1) consisted of a
literature review, identification and adaption of an existing tool, iterative testing and critical review by
experts in pharmacy, general practice, geriatric medicine and health communication/decision making.
This was followed by a formal feasibility study in the context of the Home Medicines Review
program (Stage 2) with accredited pharmacists (n = 11), older patients (n = 17) and their companions.
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Fig 1. Flow chart of development and feasibility study

2.2. Project team
A multidisciplinary team guided the literature review, development and feasibility study. The team
included experts in psychology (JJ, KMcC, CB), pharmacy (AM, DR), general practice (JD, LT),
geriatric medicine (VN), epidemiology (LI), ethics (SC), statistics (KMcG) and representatives
for consumers (JC) and NPS MedicineWise (AH).
2.3. Ethical approval
Ethical approval for the feasibility study was obtained through the Human Research Ethics Committee
of the University of Sydney (Project No. 2015/935).
2.4. Stage 1
2.4.1. Literature review
A narrative review of the literature into the challenges of shared decision makingand older patient
involvement in decisions about polypharmacy and deprescribing (careful and supervised withdrawal
of unnecessary or potentially harmful medications)22 was conducted.8 A framework was developed,
describing the key steps of shared decision making for this context that draws together knowledge
from the psychology, communication and decision-making literature. A systematic review of the
literature was also conducted by authors of this paper to identify decision support tools (n = 22) for
older people.20 Many of the tools were not considered appropriate for the aims of this study, as the
4

majority were not developed specifically for older people, and tended to focus on a single condition,
rather than accounting for comorbidities.

2.4.2. Medicines Conversation Guide
In the search for existing tools, one was identified as suitable for adaptation in the context of this
study. This tool was the Serious Illness Conversation Guide23 (created by Ariadne Labs), developed to
support patient-clinician communication at the end-of-life where goal-concordant care and
communication about values and preferences is important. It was designed for older people and
encourages discussions around broader topics related to health, and what is most important for the
individual, which is very relevant to the context of polypharmacy and deprescribing. The Serious
Illness Conversation Guide was adapted for this study by removing any specific reference to
prognosis and end-of-life care, changed the instructions for clinicians and revised some content to
focus on medicines. The resulting Medicines Conversation Guide is a structured one-page tool
designed to guide clinicians in conducting values and goals conversations around medicines. The
wording is based on the original guide, which was tested in a patient population (patient/family
advisory group and focus groups with patients, family members and clinicians). The key elements that
are addressed include: general health understanding, decision-making and information preferences,
health priorities related to medicines, patient goals and fears, views on important activities and
making trade-offs for benefit/harm and quality/quantity of life. This intervention is intentionally
designed not to influence people either towards or away from medicines, rather it aims to support
goal-concordant care which could include well-informed decisions about stopping or reducing their
medicines.
2.4.3. Iterative testing and review process
The first version was reviewed by GPs recruited through professional contacts and accredited
pharmacists recruited from the Society of Hospital Pharmacists of Australia (accredited pharmacists
specialist interest group) and the Australian Deprescribing Network (n = 8). They provided written or
verbal feedback by email, phone or in person. The tool was tested informally in the context of the
Home Medicines Review by an accredited pharmacist/researcher with 6 older patients who provided
feedback over the phone to a researcher.
The feedback from this iterative testing and review process was incorporated into version two of
the Medicines Conversation Guide (referred to hereon as the Guide). The main revisions (Table 1)
were: redesigning the format and structure, simplifying concepts such as quality of life and
benefit/harm trade-offs, and rewording questions so they were easier to understand. Previous and
current versions of the Guide can be accessed here: http://hdl.handle.net/2123/18330.
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Table 1. Summary of changes to the Medicines Conversation Guidea.
Trigger for the change

How the issue has been addressed

Rationale/Justification

TRADE-OFFS QUESTION V1:
Would you be willing to accept a
small increase in risk to your
future health for less side effects
or reducing your number of
medicines?

TRADE-OFFS QUESTION V2
(truncated):
Now we are going to work out what
matters most to you, because
different people value different
things.

FEASIBILITY STUDY
Pharmacists and patients recognised
the importance of the Trade-offs
concept but needed a more effective
way of discussing it: “what's the
patient's objective?. They could die
of old age tomorrow. So to them,
quality is probably more important
than, um, longevity, but not always”
(ID8, pharmacist).
LITERATURE/THEORY
Consumer theory: patients need to
recognise trade-offs between
different options to clarify values
and priorities, and link to
preferences.

•
Trade-offs question
difficult for patients to
understand: “maybe
could be simplified from
a daughter's point of
view to an oldie” (ID8,
patient, female, age 89,
daughter)
•
Pharmacists found the
question awkward and
clunky: “It is a mouthful
and I reckon for some
patients by the time you
got to the end of the
sentence they would've
forgotten what it is.”
(ID8, pharmacist)

•

Some people think side
effects such as aching
muscles aren't a big deal
Some people hate having
even mild side effects
•
In Version 2 the Trade-Offs
question was modified to
make it clearer for patients
to understand and easier for
pharmacists to ask and
tailor to individuals. A
preamble has been added to
give context and the
question is staged with
options for the pharmacist
to use at their discretion.

Question has been added to Version
2 that encourages patient
involvement, explores attitudes
towards medicines and openness to
deprescribing:
MAKING CHANGES
QUESTION:
Pharmacists were
How do you feel about making
concerned older patients changes to your medications?
may be unused to being
involved in decisions
PROMPT/ALTERNATIVE
about their health: "I
PHRASE:
find that they can't
To give pharmacists options, so
comprehend that kind of questions sound less formal and
concept yet … they are natural.
very elderly patients
who are so used to
getting told by the
doctors or pharmacists
Important to involve
patients in discussions
about changes to their
medicines

•

PROMPT: If patient has
unwanted side effects:

FEASIBILITY STUDY
According to some pharmacists, this
questioned supported patient
involvement: “How do you feel
about making changes to your
medication? So by that stage I had
summarised some of the information
with him that I was going to suggest
with the doctor … he said he was
happy to discuss … them with the
doctor, and that they'd be a shared
decision” (ID5, pharmacist).
LITERAUTRE/THEORY
Previous study by our team [14]
showed the importance of exploring
patients' attitudes towards medicines
and their openness to deprescribing.
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Trigger for the change

How the issue has been addressed

Rationale/Justification

Modifications have been made so
the Guide can sound more informal
and natural. An introduction has
been added for pharmacists to
introduce the discussion to patients.

FEASIBILITY STUDY
“Overall the Guide needs contextual
guidance to remind clinicians what
it’s for.” (informal feedback,
GP/researcher)

INTRODUCTION
This guide is designed to facilitate
an engaged discussion with older
patients taking multiple medicines
about their goals, preferences and
priorities in relation to their
medicines.

LITERATURE/THEORY
A Delphi panel on a consensus
definition of Advanced Care
Planning [30] reported the need to
prepare patients for goals and values
discussions by stating the purpose
and providing context.

what to do” (ID4,
pharmacist).
•
Guide questions could
sound too formal or
scripted for patients:
“sounding like you're
sort of interrogating
them" (ID1,
pharmacist).

•
Prompts and alternative
phrases have been provided
as options
to Guidequestions, in
the Guide itself and
additional intervention
components (training
module, strategies for
common scenarios/barriers)
Training module will
consolidate feasibility study
findings to instruct pharmacists
to use the Guideeffectively.

Training module is being developed FEASIBILITY STUDY
to give strategies and instructions to To integrate the Guide with HMR
use a checklist/bullet points: “Added
pharmacists:
[Guide] questions to my information
collection sheet I use for HMR's”
•
(ID8, pharmacist).
•
To relate broad responses
Guide questions could
to the patient's medicines or Older patients preferred
be too broad or
to bring the discussion back the Guidequestions interspersed with
the HMR: “she didn't specify that
tangential: “ some of the
on track,
those particular questions were from
questions I found took
[Guide]. She just asked a series of
•
us off the track from
questions in relation to what I was,
To integrate
medicines.” (ID8,
the Guidequestions with the … you know, when she was talking.
pharmacist)
And I answered it” (ID14, patient,
HMR or ask questions
•
female, age 77).
when it's most relevant.
Guide asked separately
LITERATURE/THEORY:
from the HMR: “I just
The importance of training clinicians
did my HMR as I would
in communication, shared decision
normally do it and then
making and practical application of
I left the conversation
clinical encounter tools is well
guide to the end” (ID5,
established [17, 19].
pharmacist).
a Original Serious Illness Conversation Guide created by Ariadne Labs: A Joint Center for Health
Systems Innovation (www.ariadnelabs.org) between Brigham and Women's Hospital and the
Harvard T.H. Chan School of Public Health, in collaboration with Dana-Farber Cancer Institute.
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2.4.4. Other intervention components
Additional components to applying the Guide were developed including a summary table of
recommendations from the HMR for the GP and the patient which included topics from the Guide.
Strategies for pharmacists to use the Guide and to overcome any challenges in the conversation were
developed in written form. These intervention components were developed in conjunction with the
feasibility study based on what made the Guide more or less effective to implement.

2.5. Stage 2
2.5.1. Design
The feasibility study design24,25 used mixed methods including observation, surveys and interviews
with 11 pharmacists, 17 older patients and 4 of their companions through 17 HMR consultations.
Besides a brief introduction to the overall purpose of the Guide, pharmacists were given minimal
instructions on how to incorporate the Guide into the HMR to assess how flexible it was in real
consultations. Pharmacists chose how to implement the Guide and which patients to use it with.

Box 1
Where the Medicines Conversation Guide fits in the HMR process.
Step Individuals are identified based on “clinical need” by their GP. This includes but is not
1
limited to: a recent stay in hospital; significant change in medical condition, ability or
medications; complex medication regimen
Step Referral of the patient is made to an HMR-accredited pharmacist
2
Step Pharmacist visits patient's home and conducts the medicines review and the pharmacist
3
incorporates the Medicines Conversation Guide into their usual HMR practice
Step Pharmacist documents findings and recommendations in a report for the patient's GP
4
Step A medication plan is formulated by the GP and patient based on the pharmacist's HMR
5
report. This step is at the discretion of the GP and may not always occur i.e. if no changes
are needed

2.5.2. Participants and recruitment
Accredited pharmacists were recruited through two advertisements in the Australian Association of
Consultant Pharmacy e-newsletter. Thirteen pharmacists completed the expression of interest form
but 2 were unavailable during the data collection period.
Older patients were referred for a HMR by their GP in the usual manner (see Box 1) and informed
about the study by the accredited pharmacist who received the referral. If interested, patients were
contacted by a researcher to explain the study and obtain consent. The HMRs were conducted as usual
8

in the patients' homes, if companions were present during the HMR they were interviewed over the
phone together with the patient.
2.5.3. Data collection
A semi-structured interview schedule and quantitative survey was developed by a multidisciplinary
team of experts (see Project team). The questions related to wording, clarity and appropriateness of
questions were asked (e.g. “How did you find the wording of the Guide?”). The quantitative survey
for pharmacists was based on previous work by this research group and asked about feasibility issues
such as acceptability, content and ease of use.
Basic demographic information was collected for pharmacists including years of experience with
HMRs and number of HMRs in the past 12 months. To protect the confidentiality of older patients,
only their information about age and gender were recorded.
The researcher (KW) took notes during the HMR and added more detail and reflections afterwards.
The telephone interviews with patients and pharmacists were conducted between 1 day and 2 weeks
after the HMR and lasted 7–34 min. Interviews were audio recorded and transcribed verbatim with
any identifying details removed. Pharmacists were followed up 6 months later to see they were still
using the Guide.

2.5.4. Data analysis
Framework Analysis26 was used to organize the interview data and identify themes, with participants
as rows and themes as columns. This thematic framework development involved a five-step process.
First, upon completion of the interviews one researcher (KW) read through a subset of transcripts to
identify salient themes. These themes along with the interview schedule formed the basis for the
initial coding framework which was discussed and reviewed by a group of qualitative researchers
(KW, JJ, CB, SCoh). Two researchers (KW, JJ) then independently reviewed another subset of
transcripts, developed codes, and compared the data for similarities and differences in the data and
coding. Researchers then discussed and established categories and overarching themes. Two
researchers (KW, SCoh) independently summarised the themes and supporting quotes from each
transcript with continuous discussion with other researchers. The observation notes were analyzed in
the same way as the qualitative interview data and incorporated into the excel spreadsheet.
When all of the data were coded, the framework was examined within and across themes and
participants to identify relationships and themes. Rigour was addressed throughout by ensuring a
detailed documentation of the analysis process; independent coding of a subset of transcripts, constant
comparison of new and existing data; and regular discussion of emerging and final themes.
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3. Results
The majority of pharmacists (n = 11) were female (10/11) with an average age of 51, and most had
been performing HMRs for 10 or more years (see Table 2). The older patients (n = 17) were a mix of
male and female, ranging in age from 66 to 96 years old.

Table 2. Characteristics of pharmacists and patients.
No. of Pharmacists n = 11

Pharmacist characteristics
Age (years)
25–44

4

45–64

5

≥65

2

Sex
Female

10

Male

1

Years performing HMRs (yrs)
0–9

4

10–20

3

>20

4

Number of HMRs in past 12 months
0–99

5

≥100

6

Patient characteristics

No. of Older Adults n = 17

Age (years)
65–74

1

75–84

8

≥85

9

Sex
Male

8

Female

9

Themes have been broadly categorized as ‘positive’ or ‘negative’ in relation to key areas of
acceptability, implementation and usability/practicality of the Guide. The main positive themes
related to the Guide's format and content, integration of the questions with the HMR, and potential
positive outcomes that it may improve the HMR. The negative themes pertained to how
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the Guide was delivered, understandability of some questions and concerns that the HMR was an
unsuitable setting for these types of discussions. Pharmacists differed in their approach to HMRs:
some conducted more patient-centred and less structured, conversational reviews while others were
more medicines-focused and very structured in their HMR interview. This influenced how useful
pharmacists found the Guide and perceived barriers to implementation.

3.1. Quantitative survey results
From the quantitative survey results (Table 3), most of the pharmacists thought the tone of
the Guide was neutral or positive (11/11), easy to understand (9/11) and completely balanced (9/11).
The majority of the pharmacists also found the format of the Guide was simple (8/11) and easy to use
(7/11).
Table 3. Pharmacists' responses to quantitative survey.
No. of Pharmacists n = 11

Question
The tone of the Guide was:
Positive

4

Neutral

7

Negative

0

The Guide was balanced:
Slanted towards more medications

0

Completely balanced

9

Slanted towards less medications

2

Using the Guide was:
Difficult

2

Undecided

2

Easy

7

The format of the Guide was simple:
Agree

8

11

No. of Pharmacists n = 11

Question
Neither agree or disagree

2

Disagree

1

The Guide was easy to understand:
Agree

9

Neither agree or disagree

1

Disagree

1

Will continue to use the Guide in the future:a
1–2 (not at all – slightly)

3

3 (a medium amount)

3

4–5 (a good deal – a great deal)

5

a 1 = not at all, 2 = slightly, 3 = a medium amount, 4 = a good deal, 5 = a great deal.
3.2. Positive
3.2.1. Acceptability of the format and content
Pharmacists generally found the Guide easy to use, the format was acceptable, flexible and of the
right length (Table 3): "It's not lengthy, but it's relevant and it's practical” (ID6, pharmacist). Most of
the older patients were comfortable answering the Guide questions and found them “easy to
understand, I think I answered all the questions honestly and how I felt about it" (ID1, patient, female,
age 84). Most patients found the Guide to be an appropriate addition to the HMR: "it all seemed to be
part and parcel of the proper routine. I didn't think there was anything that didn't seem to fit in with
the rest of it" (ID17, patient, male, age 88).
3.2.2. Implementation of the Guide
Based on the observations, how pharmacists delivered the Guide was an important indicator of its
effectiveness and how useful pharmacists and patients perceived it to be, "works best if you can
incorporate it with your [HMR] checklist" (ID8, pharmacist). Implementation was most successful
when pharmacists introduced topics at relevant times and tailored questions to suit the patient and
specific HMR (Table 4).
Table 4. Summary of key findings with illustrative quotes.
12

Main finding
Strengths

Selected quotes

The Guide was understandable and
made sense to pharmacists and patients

“They understood what I was asking, but also
why” (ID3, pharmacist)
“Shared decision making. I did so like that particular
phrase.” (ID14, patient, female, age 77)
“What [pharmacist] asked is 100% pertinent” (ID7,
patient, male, age 82)
“They seemed to … cover all aspects, and they
seemed to be ... relevant” (ID10, patient, male, age
96)

Integrating with the HMR enabled
the Guide to be more effective

“So doing it in the body of my HMR, was good
because … it followed through, you know, I tried to
use it as I would normally do and just change the
way I asked questions a little bit” (ID9, pharmacist)
“Use it as a guide but just tailor it to the needs of the
patient” (ID1, pharmacist)
“I have modified it and incorporated it into my own
interview guide” (ID11 pharmacist)
“I was interspersing quite a bit of it. It probably
added about … maybe 10 min to the complicated
person” (ID3, pharmacist)

The Guide introduced new concepts
“Everyone's an individual and I think zeroing back
(goals and preferences) that focused the on, what that person is going through is very
HMR on the patient's experience
important and I think those questions address that”
(ID6, pharmacist)
“What's the patient's objective? You know, they
could die of old age tomorrow. So to them, quality is
probably more important than, um, longevity, but not
always” (ID8, pharmacist)
“It was good to tell her what my main concerns,
what was worrying me the most about my health.
You know? Just to talk to someone about
it. ‘Cos when you go to the doctor, they're so busy
and … you're in and out, and … you can't, I can't
open up to doctors properly”(ID12, patient, female,
age 66)
Limitations

The Guide format was too structured
and restrictive for some pharmacists

“[HMRs] flow according, to their own riverbed, as it
were. And every one of them's different. And trying
to put a easy flowing conversation within the
strictures of a scripted sort of … can have a little bit
of a jarring tone” (ID11, pharmacist)
“Maybe the bullet point is just ‘doctor awareness’.
And that means, I've got to ask the person, do you
think the doctor's aware of … the fact that your
gout's not getting any better?” (ID11, pharmacist)

13

Main finding

Selected quotes

Some of the Guideconcepts/wording
“I find that they can't comprehend that kind of
were difficult for patients to understand concept yet … because they are usually these are
or unsuitable for a HMR
very elderly patient who are so used to getting told
by the doctors or pharmacists what to do” (ID4,
pharmacist)
“the Sydney University questions were a bit
academic and idealistic” (ID11, patient, male, age
88)
“Cause I work in some, probably quite low socioeconomic areas of [Sydney] and probably areas ...
there's a lot of Australian but it's a more down-toearth English” (ID8, pharmacist)
Pharmacist
HMR style

Some pharmacists conducted HMRs
that were more structured, timeconscious and focused on practical
aspects of medicines

“So my questions are often very … direct, like, you
know, what difficulties are you having swallowing
your medicines? Can you swallow them all whole?
Or are there any that you need to crunch or chew
up?” (ID5, pharmacist)
“We don't have enough time to cover stuff that
doesn't—that's not going to have any influence on
the actual report in the end” (ID8, pharmacist)

Some pharmacists conducted HMRs
that were less structured, more
conversational and patient-focused

“Like I've always thought that I'm patient focused.
I'm not drug focused particularly, which might sort
of sound strange” (ID3, pharmacist)
“So people may do more structured interviews than I
do, but I try to get an empathy with them. But, um …
you know, it helps. They give you more information”
(ID2, pharmacist)
“You can't ask them, oh tell me your pain score.
They can, but I guess it doesn't … sit well. That
rapport is not as good by asking … like the really
formal … very health professional based question.
And personally I prefer, the informal way” (ID4,
pharmacist)

Pharmacists reported the Guide could be naturally integrated with the HMR interview, and that this
tended to be a more effective approach than asking the two sets of questions separately. Delivering
the Guide flexibly and drawing upon relevant questions when the opportunity arose enabled
the Guide to be more effective: “it wasn't in the order. I try to make it as natural as possible. So I, you
know, while we're talking about this, how do you feel about that" (ID10, pharmacist). Another
condition in which the Guide seemed more effectively implemented was when pharmacists modified
questions to suit their language and communication style, “I didn't have to change it a lot. But I would
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change it to fit in to my conversation” (ID2, pharmacist). Pharmacists discussed modifying the
questions to meet the patient's needs and level of understanding. Pharmacists that conducted more
patient-centred (rather than structured) HMRs reported finding it easier to adapt the Guide and
incorporate it with their own HMR interview.
Some of the older patients interviewed reflected the importance of interspersing the Guide questions
with the pharmacist's HMR interview: “I think she was slipping them in …. I think a lot of the
questions she asked were actually hidden through the whole thing” (ID15, patient, female, age 74).
This also added to the perceived relevance of the Guide and contributed to how comfortable a patient
was to answer.
3.2.3. Practicality and usability
Pharmacists discussed how the Guide was more suitable for certain patient characteristics or HMRs,
with mixed responses. Some said it was most useful with patients who had less complex medicines
reviews (i.e. no problems with their medicines), (n)one chronic conditions: “She just had such a
simple regiment that, that I could use the Guide” (ID3, pharmacist). Others found it was especially
beneficial for patients with multi-morbidities or complex chronic conditions on a high number of
medicines: “the tool's definitely useful but to what extent the usefulness depends on the complexity of
the case. It will be very useful for people who suffer from, for example, pain. Or depression. That type
of chronic condition" (ID4, pharmacist). Some pharmacists noted the Guide may be useful in other
contexts such as general practice with an integrated pharmacist, in primary care or multi-disciplinary
setting delivered by a GP, nurse or allied health professional.
Pharmacists reported the Guide was an acceptable addition in terms of timing and this was also
reflected in the quantitative survey (Table 3) and observations. The majority of pharmacists said they
would continue using at least some questions from the Guide, with some continuing to use
the Guide when followed up 6 months later.
3.2.4. Potential impact of the Guide and added value
The findings from this study suggest that the Guide added value to the HMR process by introducing
new concepts that facilitated communication between the patient, pharmacist and GP (Table 4).
Pharmacists found the introduction of the concepts goals and preferences focused the HMR on the
patient's experience not just the referring GP: “It puts you, more mindful of the patient's point of view,
which is really what we're there for. Not just for GPs …” (ID10, pharmacist). This structured
approach to facilitating patient involvement seemed to lead to a more collaborative HMR process, for
instance fortifying recommendations with patient priorities: "then you can recommend that to the GP
in your report to say Mr and Mrs Smith think that they would like to cut down on the number of
medications" (ID1, pharmacist). Similarly, the ‘Trade-offs’ question facilitated discussion about
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priorities around discontinuing medications, quality of life and longevity and importantly,
communicating this to the GP: “opening the door ... is your GP actually aware of what's important to
you to see whether or not they've had that conversation with the GP” (ID1, pharmacist).
Older patients appreciated how the Guide encouraged a more holistic view on health: “it helped to
focus the mind, in regards to health in general” (ID7, patient, male, age 82, partner), and provided the
space to open up “other avenues for things … that are at the back of my mind" (ID14, patient, female,
age 77). Some older patients reported they found it valuable to vocalize their concerns and to have the
opportunity to do so.

3.3. Negative
3.3.1. Acceptability of the wording and understandability
Some pharmacists highlighted problems with the wording of the Guide questions as sounding too
formal when read out loud: "they look good but I think when I went to say them they weren't quite
right" (ID8, pharmacist); "they're 65, they're not used to the formal way of questioning" (ID4,
pharmacist) (Table 4). Pharmacists who had a less structured approach to HMRs found the Guide too
restrictive.
Some of the older patients stated that a few of the Guide questions were difficult to grasp the meaning
of (Table 4). One patient who had a health background noted, “I suppose considering our age and
education level it's probably easier for us than it might have been for someone else” (ID7, patient,
male, age 82). Some older patients suggested the questions were too academic or complicated:
“maybe could be simplified from a daughter's point of view to an oldie” (ID8, patient, female, age 89,
daughter).
Some pharmacists stated that the Guide questions were less suitable for patients who speak English as
a second language or from a lower socio-economic background: “I can't ask these to most of the
people … I deal with … They wouldn't understand it because, I do a lot of first generation immigrants
…” (ID2, pharmacist).
3.3.2. Implementation and perceived appropriateness of the Guide
Some pharmacists reported asking the Guide questions separately at the beginning or end of the HMR
interview. This often meant it didn't flow with the pattern of the HMR, issues weren't addressed when
they came up and the questions were disconnected. These barriers were more often experienced by
pharmacists that conducted more medicines-focused reviews, "I realized that it would have been a
better experience for the patient if I kind of integrated the questions" (ID4, pharmacist). When asked
at the beginning, it seemed too direct or upfront for older patients: “I just think as a whole, more of a
general conversation. I know with Mum, it's easier to get information … if you're just talking, rather
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than firing questions” (ID8, patient, female, age 89, daughter). One pharmacist suggested key words
rather than questions may help integrate the Guide.

Pharmacists suggested that concepts raised by the Guide were difficult for older patients to grasp
because they were unfamiliar with being involved in health decisions. Similarly, pharmacists queried
whether a GP should discuss goals and preferences with their patient instead: "If they're not used to
having those discussions, are we the people during an HMR to start having these discussions or do
the GPs need to be re-educated and then we need to re-introduce that question" (ID7, pharmacist).
3.3.3. Practicality and usability
Some pharmacists reported that some of the Guide questions were not suitable for the context of a
HMR. Some pharmacists were tentative to use the terms ‘fears’ and ‘worries’ if the patient had not
raised any themselves, due to concern the patient might become upset: "I think it could become a bit,
… intimidating. ‘Cause there's lot of words that … might sound a bit scary" (ID10, pharmacist). A
few pharmacists felt the Guide could lead the patient on tangents unrelated to medicines: "some of the
questions I found took us off the track from medicines. And on to things like social or physio, and
while I can give advice on dietary and stuff like that, I haven't got time … " (ID8, pharmacist). This
could be difficult for pharmacists who were very medicines-focused and led structured HMRs without
many open-ended questions.

Although the Guide appeared to combine well with the HMR logistically, some older patients noticed
the HMR seemed like a long time, but this varied depending on the pharmacists' HMR style and
complexity of patient characteristics or medications. Some older patients stated the Guide questions
were difficult to answer because of the high cognitive burden or because the problem felt too big to
address: “I could have not answered more anything because, …I'm just in pain and somehow I feel
that … I can't have any help. First of all I'm old also and, and I can't explain … properly” (ID6,
patient, female, age 89). One patient felt the purpose of the Guide was not relevant to him: “I'm nearly
88 … I concentrate on survival. I'm not looking for, I can't afford to look at, … picking up extra
benefits out of life. I'm just a survivor” (ID11, patient, male, age 88).

4. Discussion
This paper describes the development and investigates the feasibility of the Medicines Conversation
Guide as an additional component of HMRs for older people taking multiple medicines. The
acceptability and implementation of the Guide was assessed from the perspective of pharmacists,
older patients and their companion or carer (if present at the HMR).

17

Findings from the quantitative survey indicated the Guide was simple to implement, understandable,
balanced and generally positive in tone. Feedback from pharmacists and older patients from the
qualitative interviews showed the Guide to be an overall acceptable addition to the HMR. A few
challenges were identified in terms of implementation and the Guide questions were difficult for some
patients to understand. Some of the pharmacists thought a few of the questions in the Guideshould not
be asked in a HMR rather should be addressed by the patient's GP.

There were two main positive findings that highlight how the Guide could be successfully
implemented in the context of HMRs. Firstly, delivery of the Guidequestions was most effective when
pharmacists integrated questions with their usual HMR interview. Pharmacists who tended to conduct
less structured HMRs in a naturally conversational style found the Guide easier to implement by
adapting it to suit their communication style and the needs of the patient. Secondly, the Guidewas
found to support communication about preferences and goals which was achieved by focusing the
HMR and recommendations to the GP on the patient's priorities. This is significant, as recent findings
from systematic reviews of polypharmacy interventions and medicines reviews have highlighted
limited patient involvement. Patient-reported outcomes were not a priority for most RCTs of
medicines reviews27 and few studies of pharmacist-led interventions discussed medication changes
with the patient or provided sufficient information about patient involvement.28

There were two main barriers to implementation of the Guide reported by some pharmacists and
patients. Some pharmacists delivered the Guide separately from the rest of the HMR. Pharmacists
differed in relation to this barrier, with pharmacists that conducted less structured reviews struggling
to adjust to the strictures of the Guide layout/content. Pharmacists with a more structured HMR style
had difficulty incorporating the Guide, so delivery could sound too formal or stilted. Patients reported
the questions sounded interrogatory and appeared less comfortable answering questions when they
were not integrated in the HMR interview. This barrier may be overcome by training and skill
development which has improved the use of other tools such as clinical encounter guides and decision
aids.18,29 Another possible way to overcome this barrier would be to integrate the Guide with the
clinical environment by linking it with an electronic medical record or other digital system. However,
this would require system level changes as HMRs are currently conducted in the patient's home with
no standard process for conducting or reporting HMRs.30

The second negative aspect related to perceptions of some pharmacists that the Guide was not suitable
for a HMR context because certain topics such as changing medications and trade-offs should be
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raised by a GP instead. For these pharmacists and patients, the acceptability of the Guide was lower.
Even though pharmacists may have the opportunity during HMRs to discuss topics such as goals and
preferences and make recommendations accordingly, this is not without challenges in clinical
practice. Although the Guide was tested in the context of the existing HMR program, pharmacist
participants recognized the applicability of the tool in other contexts – which may be explored in the
future – delivered by GPs or practice nurses in the clinic setting or by staff in residential aged
care facilities. Studies have found that discussions about goals and preferences are not embedded in
routine care and clinicians may not be comfortable having these conversations for a number of
reasons: being wary of overstepping professional boundaries, devolved responsibility, lack of
communication between health professionals, and competing priorities.31,32 Although the difficulties
should not be overlooked, starting this conversation is important.

Furthermore, discussing patient goals and preferences comes naturally for some clinicians but can be
difficult and counter-intuitive for others. HMRs are conducted heterogeneously and understanding
how pharmacists are using the Guide in practice is helpful for implementation and further
development of the intervention. Although the pharmacist HMR styles differed, all found
the Guide useful to some extent and the majority stated they would continue to use the Guide in some
form. These findings are informative as there are no guidelines available for developing or testing this
type of intervention. To improve implementation of the Guide, these findings will inform a training
module including components such as a flexible format, strategies for practical use/common barriers,
role-play activities, guidance for prioritizing questions so as not to overburden any patients and
suggestions for prompts or question alternatives that bring the conversation back to medications.
This study is rare in that few other reported studies focus on older patients' preferences, goals and
values in the context of medicines. The Medicines Conversation Guide is the first intervention to
focus on optimizing medicines in older people and the role of preferences and goals in this context. It
demonstrates the importance of beginning a meaningful conversation and creating the space to hear
the patient's perspective. What follows after the HMR may involve iterative conversations that take
place over multiple consultations, coordinated care with all health care providers,33 clinical tools
(algorithms or decisions aids) to prioritize specific medications that can be safely reduced or
stopped,22 and involving companions/family member(s) if preferred by the patient.34
Limitations of this study include the small sample size and a predominantly female sample of
pharmacists – although this gender ratio reflects the workforce population of accredited pharmacists
to some extent.35 Pharmacists used the Guidewith an average of two patients so depending on the
patient/HMR not all questions may have been asked. It was difficult for older patients to distinguish
the Medicines Conversation Guide questions from the regular HMR interview and for many of the
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patients it was their first HMR so they were unable to compare it to anything else. Lastly,
recommendations made by the pharmacists were not followed through to the GP, meaning decisions
made subsequently to the HMR are not known to us.

Moving forward, showing that using the Guide in HMRs can effectively influence how GP's manage
medication in older people, and results in better patient outcomes is the ultimate aim of this research
program. The next steps are to focus on the GP's perspective to determine if the information from
the Guide would improve the HMR report and help inform GP's management of their older patients.
Following this, it would be useful to assess the impact of the Guide in a larger scale research project
that captures rich data at each step of the HMR process involving the patient (and carer/family
member), pharmacist and GP.

5. Conclusions
This research group developed the Medicines Conversation Guide designed to support discussions
about patient priorities and goals in the context of medicines. The findings of the study described in
this paper look promising in terms of increasing patient involvement and engaging older people in
discussions about their medicines. To improve the value of the Guide, further consideration should be
given to training clinicians about how to use the Guide with their patients and supporting pharmacists
to tailor the Guide so that it is relevant and meets the needs of individual patients. The importance of
follow-up with the patient's GP cannot be underestimated as well as promoting the patient's
perspective in any decision about medicines.
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